We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
2016 has been a busy year for the Biotech industry. Let’s take a look 5 of the strongest year-to-date (YTD) performers.
Here are five Biotech stocks that have experienced a YTD price change of >20% and sit at a Zacks Rank #2 (Buy) or better:
Ani Pharmaceutical (ANIP - Free Report) is a specialty pharmaceutical company that develops generic prescription medicines. Their products range from cough/cold products to laxatives, amongst others.
ANIP has gained 23.7% YTD, and has a 100% agreement in upward earnings estimate revisions for this fiscal year. Analysts have revised Q2 estimates to $0.87 per share, up from $0.44 60 days ago.
ANIP currently sits at a Zacks Rank #1 (Strong Buy).
Argos Therapeutic develops personalized immunotherapies for the treatment of cancer and other infectious diseases.
ARGS has gained a stellar 165.4% YTD, and has a 100% agreement upward in earnings estimate revisions for this fiscal year and 75% Agreement for next fiscal year. Analysts have revised Q2 estimates to -$0.40 per share, up from $-0.52 per share 60 days ago.
Xbiotech Inc. (XBIT - Free Report) discovers and develops monoclonal antibodies for treating diseases under their “True Human” brand.
XBIT has gained 92.5% YTD, and has 100% agreement in upward earnings estimate revisions for this fiscal year. Analysts have revised Q2 earnings estimates to -$0.38 per share, up from -$0.43 per share 60 days ago.
Opexa Therapeutic develops cell therapies to treat autoimmune diseases such as MS (multiple sclerosis), rheumatoid arthritis, and diabetes.
OPXA has gained 49.1% YTD, and has 100% agreement in upward earnings estimate revisions for this fiscal year. Current Q2 estimates sit at -$0.35 per share and have not been revised in 60 days, but analysts estimate earnings of $0.50 per share next fiscal year.
Repros Therapeutic (RPRX - Free Report) develops products for the human reproductive system.
RPRX has gained 33% YTD, and has 100% agreement in upward earnings estimate revisions for this fiscal year. Currently, there are no estimates for Q2 earnings, however estimates for this fiscal year are at -$0.74 per share, up from -$0.77 60 days ago.
While these stocks have surged, they are all still looking great from an earnings estimate revision perspective. This suggests that these stocks could continue to see even more gains ahead. Any of them may still be worth a closer look even though they have already started 2016 on a very positive note.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
5 Top Biotech Performers of 2016
2016 has been a busy year for the Biotech industry. Let’s take a look 5 of the strongest year-to-date (YTD) performers.
Here are five Biotech stocks that have experienced a YTD price change of >20% and sit at a Zacks Rank #2 (Buy) or better:
Ani Pharmaceutical (ANIP - Free Report) is a specialty pharmaceutical company that develops generic prescription medicines. Their products range from cough/cold products to laxatives, amongst others.
ANIP has gained 23.7% YTD, and has a 100% agreement in upward earnings estimate revisions for this fiscal year. Analysts have revised Q2 estimates to $0.87 per share, up from $0.44 60 days ago.
ANIP currently sits at a Zacks Rank #1 (Strong Buy).
ANI PHARMACEUT Price
ANI PHARMACEUT Price | ANI PHARMACEUT Quote
Argos Therapeutic develops personalized immunotherapies for the treatment of cancer and other infectious diseases.
ARGS has gained a stellar 165.4% YTD, and has a 100% agreement upward in earnings estimate revisions for this fiscal year and 75% Agreement for next fiscal year. Analysts have revised Q2 estimates to -$0.40 per share, up from $-0.52 per share 60 days ago.
ARGS currently sits at a Zacks Rank #2 (Buy).
ARGOS THERAPEUT Price
ARGOS THERAPEUT Price | ARGOS THERAPEUT Quote
Xbiotech Inc. (XBIT - Free Report) discovers and develops monoclonal antibodies for treating diseases under their “True Human” brand.
XBIT has gained 92.5% YTD, and has 100% agreement in upward earnings estimate revisions for this fiscal year. Analysts have revised Q2 earnings estimates to -$0.38 per share, up from -$0.43 per share 60 days ago.
XBIT currently sits at Zacks Rank #2 (Buy).
XBIOTECH INC Price
XBIOTECH INC Price | XBIOTECH INC Quote
Opexa Therapeutic develops cell therapies to treat autoimmune diseases such as MS (multiple sclerosis), rheumatoid arthritis, and diabetes.
OPXA has gained 49.1% YTD, and has 100% agreement in upward earnings estimate revisions for this fiscal year. Current Q2 estimates sit at -$0.35 per share and have not been revised in 60 days, but analysts estimate earnings of $0.50 per share next fiscal year.
OPXA currently sits at a Zacks Rank #2 (Buy).
OPEXA THERAPEUT Price
OPEXA THERAPEUT Price | OPEXA THERAPEUT Quote
Repros Therapeutic (RPRX - Free Report) develops products for the human reproductive system.
RPRX has gained 33% YTD, and has 100% agreement in upward earnings estimate revisions for this fiscal year. Currently, there are no estimates for Q2 earnings, however estimates for this fiscal year are at -$0.74 per share, up from -$0.77 60 days ago.
RPRX currently sits at a Zacks Rank #2 (Buy).
REPROS THERAPEU Price
REPROS THERAPEU Price | REPROS THERAPEU Quote
Bottom Line
While these stocks have surged, they are all still looking great from an earnings estimate revision perspective. This suggests that these stocks could continue to see even more gains ahead. Any of them may still be worth a closer look even though they have already started 2016 on a very positive note.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>